ACM
ACT Capital Management Portfolio holdings
AUM
$72.5M
This Quarter Return
-15.78%
1 Year Return
-33.17%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$71.5M
AUM Growth
+$71.5M
(-24%)
Cap. Flow
-$3.12M
Cap. Flow
% of AUM
-4.36%
Top 10 Holdings %
Top 10 Hldgs %
68.62%
Holding
96
New
11
Increased
5
Reduced
26
Closed
18
Top Buys
| 1 |
Exxon Mobil
XOM
|
$4.87M |
| 2 |
Chevron
CVX
|
$2.32M |
| 3 |
Devon Energy
DVN
|
$2.09M |
| 4 |
Energy Transfer Partners
ET
|
$1.28M |
| 5 |
Adtran
ADTN
|
$1.14M |
Top Sells
| 1 |
NVIDIA
NVDA
|
$4.23M |
| 2 |
Arrowhead Research
ARWR
|
$2.32M |
| 3 |
Lantheus
LNTH
|
$1.79M |
| 4 |
Stratasys
SSYS
|
$1.66M |
| 5 |
Range Resources
RRC
|
$911K |
Sector Composition
| 1 | Healthcare | 67.46% |
| 2 | Energy | 21.36% |
| 3 | Technology | 7.48% |
| 4 | Materials | 1.27% |
| 5 | Communication Services | 1.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
STAAR Surgical
STAA
$1.36B
| $16.2M | 22.71% | 228,900 -9,200 | -4% | -$653K |
|
|
2
Exxon Mobil
XOM
$487B
| $4.87M | 6.82% | +56,900 | New | +$4.87M |
|
|
3
Arrowhead Research
ARWR
$3.05B
| $4.75M | 6.65% | 135,000 -66,000 | -33% | -$2.32M |
|
|
4
Devon Energy
DVN
$22.9B
| $4.55M | 6.36% | 82,500 +38,000 | +85% | +$2.09M |
|
5
Krystal Biotech
KRYS
$4.27B
| $3.87M | 5.42% | 59,000 | – | – |
|
6
Arcturus Therapeutics
ARCT
$462M
| $3.57M | 4.99% | 226,600 -26,700 | -11% | -$420K |
|
7
Clearside Biomedical
CLSD
$28.9M
| $3.36M | 4.7% | 2,288,200 -170,400 | -7% | -$251K |
|
|
8
Chevron
CVX
$324B
| $2.82M | 3.95% | 19,500 +16,000 | +457% | +$2.32M |
|
|
9
Adtran
ADTN
$751M
| $2.63M | 3.68% | 150,000 +65,000 | +76% | +$1.14M |
|
10
IDEAYA Biosciences
IDYA
$2.15B
| $2.39M | 3.35% | 173,500 | – | – |
|
|
EIGR
11
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $1.58M | 2.2% | 250,000 | – | – |
|
12
enVVeno Medical
NVNO
$15.4M
| $1.52M | 2.12% | 401,200 | – | – |
|
13
INmune Bio
INMB
$54M
| $1.42M | 1.98% | 160,500 -70,000 | -30% | -$619K |
|
|
14
Energy Transfer Partners
ET
$60.8B
| $1.28M | 1.78% | +127,800 | New | +$1.28M |
|
15
Unity
U
$16.7B
| $968K | 1.35% | +26,300 | New | +$968K |
|
|
16
Stratasys
SSYS
$906M
| $937K | 1.31% | 50,000 -88,500 | -64% | -$1.66M |
|
17
Vital Energy
VTLE
$690M
| $882K | 1.23% | +12,800 | New | +$882K |
|
|
AFMD
18
DELISTED
Affimed
AFMD
| $855K | 1.2% | 308,800 | – | – |
|
|
19
Lantheus
LNTH
$3.73B
| $852K | 1.19% | 12,900 -27,100 | -68% | -$1.79M |
|
|
ICAD
20
DELISTED
iCAD Inc
ICAD
| $820K | 1.15% | 205,000 -89,500 | -30% | -$358K |
|
|
MYOV
21
DELISTED
Myovant Sciences Ltd.
MYOV
| $808K | 1.13% | 65,000 -20,000 | -24% | -$249K |
|
22
CF Industries
CF
$14B
| $772K | 1.08% | +9,000 | New | +$772K |
|
23
Inhibikase Therapeutics
IKT
$134M
| $696K | 0.97% | 937,500 -139,000 | -13% | -$103K |
|
24
Maravai LifeSciences
MRVI
$350M
| $696K | 0.97% | +24,500 | New | +$696K |
|
25
Aurinia Pharmaceuticals
AUPH
$1.58B
| $513K | 0.72% | 51,000 -16,500 | -24% | -$166K |
|